CVS Health Valuation
Is CVSD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CVSD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CVSD (€52.05) is trading below our estimate of fair value (€201.78)
Significantly Below Fair Value: CVSD is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CVSD?
Key metric: As CVSD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is CVSD's PE Ratio? | |
|---|---|
| PE Ratio | 13.3x |
| Earnings | US$5.02b |
| Market Cap | US$66.93b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.4x |
| Enterprise Value/EBITDA | 9.9x |
| PEG Ratio | 0.8x |
Price to Earnings Ratio vs Peers
How does CVSD's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 25.1x | ||
IDHC Integrated Diagnostics Holdings | 13.6x | 23.7% | US$225.8m |
CI Cigna Group | 29.5x | 24.4% | US$89.4b |
SN. Smith & Nephew | 35.3x | 22.5% | UK£8.6b |
MDC Mediclinic International | 21.9x | 10.7% | UK£3.7b |
CVSD CVS Health | 13.3x | 17.5% | €66.9b |
Price-To-Earnings vs Peers: CVSD is good value based on its Price-To-Earnings Ratio (13.3x) compared to the peer average (25.7x).
Price to Earnings Ratio vs Industry
How does CVSD's PE Ratio compare vs other companies in the European Healthcare Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: CVSD is good value based on its Price-To-Earnings Ratio (13.3x) compared to the European Healthcare industry average (18.2x).
Price to Earnings Ratio vs Fair Ratio
What is CVSD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 13.3x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CVSD's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €52.05 | €65.06 +25.0% | 13.3% | €88.34 | €55.09 | n/a | 25 |
| Nov ’25 | €52.09 | €64.39 +23.6% | 14.4% | €86.22 | €54.70 | n/a | 25 |
| Oct ’25 | n/a | €60.07 0% | 14.0% | €83.22 | €52.79 | n/a | 25 |
| Sep ’25 | n/a | €60.10 0% | 13.0% | €83.10 | €52.72 | n/a | 25 |
| Aug ’25 | n/a | €62.66 0% | 13.1% | €86.03 | €53.65 | n/a | 25 |
| Jul ’25 | n/a | €64.35 0% | 13.4% | €86.61 | €54.95 | n/a | 26 |
| Jun ’25 | n/a | €63.62 0% | 13.5% | €85.73 | €54.39 | n/a | 26 |
| May ’25 | n/a | €79.21 0% | 10.8% | €94.47 | €56.12 | n/a | 26 |
| Apr ’25 | n/a | €81.91 0% | 7.5% | €94.31 | €70.50 | n/a | 26 |
| Mar ’25 | n/a | €83.03 0% | 7.0% | €95.30 | €71.24 | n/a | 25 |
| Feb ’25 | €68.12 | €83.22 +22.2% | 7.4% | €95.46 | €73.43 | n/a | 24 |
| Jan ’25 | n/a | €80.28 0% | 8.6% | €94.43 | €69.01 | n/a | 24 |
| Dec ’24 | €61.24 | €80.74 +31.8% | 9.2% | €95.52 | €69.81 | n/a | 23 |
| Nov ’24 | n/a | €85.35 0% | 10.4% | €104.09 | €71.92 | €52.09 | 23 |
| Oct ’24 | n/a | €86.55 0% | 10.3% | €104.08 | €71.91 | n/a | 24 |
| Sep ’24 | n/a | €85.69 0% | 9.8% | €102.11 | €70.55 | n/a | 24 |
| Aug ’24 | n/a | €85.86 0% | 12.2% | €109.26 | €65.56 | n/a | 23 |
| Jul ’24 | n/a | €91.39 0% | 16.6% | €131.57 | €69.93 | n/a | 24 |
| Jun ’24 | €64.70 | €93.41 +44.4% | 16.6% | €133.29 | €70.84 | n/a | 23 |
| May ’24 | €66.41 | €99.52 +49.9% | 13.3% | €130.34 | €78.39 | n/a | 22 |
| Apr ’24 | €68.63 | €103.83 +51.3% | 10.0% | €131.12 | €87.11 | n/a | 21 |
| Mar ’24 | n/a | €107.57 0% | 9.4% | €134.88 | €89.60 | n/a | 21 |
| Feb ’24 | n/a | €108.31 0% | 6.5% | €120.47 | €92.67 | €68.12 | 23 |
| Jan ’24 | n/a | €112.17 0% | 4.9% | €123.16 | €100.42 | n/a | 23 |
| Dec ’23 | n/a | €114.03 0% | 4.9% | €124.98 | €101.91 | €61.24 | 23 |
| Nov ’23 | n/a | €122.05 0% | 5.8% | €132.87 | €102.21 | n/a | 23 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Guerbet
€339.2m
Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.
0ELV
€27.00
7D
-9.8%
1Y
50.2%
Arjo
SEK 9.2b
Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.
0HQ8
SEK 33.92
7D
-4.8%
1Y
-9.6%
Fagron
€1.3b
A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
0HNZ
€18.06
7D
-6.1%
1Y
5.3%